The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to ...

Lee — With a proposal by Vertex Towers LLC for a special permit to construct a 150-foot cell tower on Beaver Dam Road, the ...

In this webinar, sponsored by IPG Health, we will explore the role that cell and gene therapies can play in treating rare diseases, the unique challenges faced by pharmaceutical companies, healthcare ...

Many individual radio models are supported by Hamlib ... 20200114.0 Alpha RIG_MODEL_FT980 1032 Yaesu FTDX-5000 20210130.0 Stable RIG_MODEL_FTDX5000 1033 Vertex Standard VX-1700 20200320.0 Alpha ...

A/Prof Luca Casagrande and Dr Jie Yu Magnetic fields in galaxies Using numerical simulations and radio observations to determine the ... and supported with additional funding, beyond the standard ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...